Insiders | Shares | % | Avg Price | Total $ | |
---|---|---|---|---|---|
Buys | 0 | ||||
Sells | 8 | -1.16M | 100% | $67.13 | -$77.9M |
Net | -8 | -1.16M | -100% | -$77.9M |
Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Christopher D. Alafi | Director | $377M | May 27, 2021 | ||
Sharon Mates | Chairman and CEO, Director | $79.9M | -$47.2M | -37.1% | Aug 29, 2024 |
Rory B. Riggs | Director | $8M | -$337K | -4.04% | Jun 28, 2024 |
Richard A. Lerner | Director | $7.16M | Sep 30, 2021 | ||
Joel S. Marcus | Director | $3.87M | -$1.81M | -31.8% | Jun 23, 2024 |
Mark Neumann | EVP, Chief Commercial Officer | $2.72M | -$6.47M | -70.4% | Aug 16, 2024 |
Sanjeev Narula | Executive Vice President & CFO | $2.4M | Aug 12, 2024 | ||
Suresh K. Durgam | EVP, Chief Medical Officer | $1.82M | -$7.15M | -79.8% | Mar 7, 2024 |
Robert L. Van Nostrand | Director | $777K | -$2.98M | -79.3% | Jun 28, 2024 |
Michael Halstead | EVP and General Counsel | $537K | -$8.73M | -94.2% | Mar 7, 2024 |
Lawrence J. Hineline | SVP of Finance, CFO | $372K | -$3.21M | -89.6% | Mar 7, 2024 |
Eduardo Rene Salas | Director | $118K | Jun 23, 2024 | ||
Michael Rawlins | Director | Jun 9, 2022 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|